Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BLTE Belite Bio, Inc.

Post-Mkt 08-06 16:45:34 EDT

160.67

+2.17

+1.37%

盘后160.67

+0.000.00%

16:10 EDT

High162.20	Low157.26	Vol133.42K
Open158.50	D1 Closing158.50	Amplitude3.12%
Mkt Cap6.42B	Tradable Cap3.09B	Total Shares39.97M
T/O21.47M	T/O Rate0.69%	Tradable Shares19.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BLTE","market":"US","secType":"STK","nameCN":"Belite Bio, Inc.","latestPrice":160.67,"timestamp":1786046400000,"preClose":158.5,"halted":0,"volume":133416,"hourTrading":{"tag":"盘后","latestPrice":160.67,"preClose":160.67,"latestTime":"16:10 EDT","volume":1555,"amount":249841.84999999998,"timestamp":1786047005002,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.013690851735015695,"floatShares":19204800,"shares":39965314,"eps":-2.544332,"marketStatus":"Post-Mkt","change":2.17,"latestTime":"08-06 16:45:34 EDT","open":158.5,"high":162.2,"low":157.255,"amount":21466170,"amplitude":0.031199,"askPrice":169.56,"askSize":500,"bidPrice":157.46,"bidSize":12,"shortable":3,"etf":0,"ttmEps":-2.544332,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1786060800000},"marketStatusCode":4,"adr":0,"adrRate":1,"listingDate":1651204800000,"exchange":"NASDAQ","adjPreClose":158.5,"postHourTrading":{"tag":"盘后","latestPrice":160.67,"preClose":160.67,"latestTime":"16:10 EDT","volume":1555,"amount":249841.84999999998,"timestamp":1786047005002,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.793992},"requestUrl":"/m/hq/s/BLTE","defaultTab":"news","newsList":[{"id":"2657634858","title":"Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657634858","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657634858?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Aug.  06, 2026  (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeti","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340178/0/en/Belite-Bio-to-Host-Webcast-on-August-13-2026-to-Discuss-Second-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653353147","title":"3 U.S. Drug Manufacturing Stocks Investors Are Watching As Tariffs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2653353147","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653353147?lang=en_us&edition=fundamental","pubTime":"2026-07-22 11:30","pubTimestamp":1784691011,"startTime":"0","endTime":"0","summary":"Tariffs on imported generic drugs are set to rise sharply over the next few years, and that kind of policy shock rarely stays contained to one corner of the market. For investors, the question is which U.S. pharmaceutical and biotech manufacturing stocks might stand to benefit if production shifts closer to home, and which could face new pressures through supply chain or pricing risks. This article looks at how the new tariff path could affect larger domestic drug manufacturers and contract...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/3-us-drug-manufacturing-stocks-investors-are-watching-as-tar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/3-us-drug-manufacturing-stocks-investors-are-watching-as-tar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ADMA","BK4526","BK4588","ONC","BK4211","BK4585","BK4007","ISBC","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653212425","title":"Will Tinlarebant’s First-in-Disease Data and FDA Filing Change Belite Bio’s (BLTE) Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2653212425","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653212425?lang=en_us&edition=fundamental","pubTime":"2026-07-20 21:20","pubTimestamp":1784553614,"startTime":"0","endTime":"0","summary":"Belite Bio recently presented new data on its oral therapy tinlarebant at multiple ophthalmology conferences, highlighting that it met the primary endpoint of reducing lesion growth in Stargardt disease type 1 and reporting positive secondary endpoint findings, following completion of a New Drug Application submission to the U.S. Food and Drug Administration.\nThe company’s update that tinlarebant is the first therapeutic candidate to show clinical efficacy in Stargardt disease type 1 raises...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/will-tinlarebants-first-in-disease-data-and-fda-filing-chang","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/will-tinlarebants-first-in-disease-data-and-fda-filing-chang","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","LABU","BK4588","BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652218775","title":"Belite Bio Announces Oral Presentation at the Asrs Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2652218775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652218775?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:00","pubTimestamp":1784548803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nTUA9CHZ2R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652180452","title":"Belite Bio - Tinlarebant Well Tolerated in Phase 3 Dragon Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2652180452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652180452?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:00","pubTimestamp":1784548803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nTUA9CHZ2R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652213326","title":"Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2652213326","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652213326?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:00","pubTimestamp":1784548800,"startTime":"0","endTime":"0","summary":"Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease type 1, having met the primary efficacy endpoint, reduction in lesion growth Presentation to includ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/20/3329667/0/en/Belite-Bio-Announces-Oral-Presentation-at-the-ASRS-Annual-Meeting-Featuring-Additional-Positive-Secondary-Endpoint-Data-from-the-Phase-3-Trial-of-Tinlarebant-in-Stargardt-Disease-T.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651468556","title":"Belite Bio Joins H.C. Wainwright Ophthalmology Virtual Conference Panel July 22","url":"https://stock-news.laohu8.com/highlight/detail?id=2651468556","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651468556?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:03","pubTimestamp":1784117030,"startTime":"0","endTime":"0","summary":"Belite Bio joins H.C. Wainwright ophthalmology virtual conference panel July 22Belite Bio scheduled to join a panel at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL67HYNW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4007","LU2210149790.SGD","SG9999014005.SGD","SG9999014021.USD","SG9999014039.USD","BLTE","BK4585","LU0314104364.USD","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4588","IE00BGHQF748.EUR","BK4112","BCDF","IE00BN0W2T93.GBP","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651433891","title":"Mizuho Securities Sticks to Their Buy Rating for Belite Bio, Inc. ADR (BLTE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651433891","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651433891?lang=en_us&edition=fundamental","pubTime":"2026-07-13 23:55","pubTimestamp":1783958110,"startTime":"0","endTime":"0","summary":"In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Belite Bio, Inc. ADR, with a price target of $215.0...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-belite-bio-inc-adr-blte-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-belite-bio-inc-adr-blte-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SAPH","APIE","CVY","DIVL","BLTE","DINT","MFG","AADR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649957242","title":"How Phase 3 DRAGON Trial Data Showcases At Major Conferences At Belite Bio (BLTE) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2649957242","media":"Simply Wall St.","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649957242?lang=en_us&edition=fundamental","pubTime":"2026-07-08 11:27","pubTimestamp":1783481279,"startTime":"0","endTime":"0","summary":"Belite Bio recently announced that Phase 3 DRAGON trial data for its oral retinal therapy tinlarebant in adolescent Stargardt disease were selected for oral presentations at the ISCEV 2026 Symposium in Sydney and the ASRS 2026 Annual Meeting in Montréal.\nThese high‑profile clinical and ophthalmology conferences give external experts a platform to scrutinize and contextualize tinlarebant’s Phase 3 results and regulatory designations, which can shape perceptions of the program’s therapeutic...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/how-phase-3-dragon-trial-data-showcases-at-major-conferences","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/how-phase-3-dragon-trial-data-showcases-at-major-conferences","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649214856","title":"Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2649214856","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649214856?lang=en_us&edition=fundamental","pubTime":"2026-07-06 20:00","pubTimestamp":1783339200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, July  06, 2026  (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/06/3322356/0/en/Belite-Bio-to-Participate-in-the-Piper-Sandler-Virtual-Ophthalmology-Investor-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649625155","title":"Belite Bio to Present Phase 3 Dragon Tinlarebant Topline Results at ISCEV Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2649625155","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649625155?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:00","pubTimestamp":1783335654,"startTime":"0","endTime":"0","summary":"Belite Bio to present Phase 3 DRAGON tinlarebant topline results at ISCEV symposiumBelite Bio scheduled oral presentations of topline Phase 3 DRAGON results for tinlarebant in adolescent Stargardt dis","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL19pj0f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014021.USD","NDAQ","SG9999014039.USD","BLTE","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014005.SGD","LU2210149790.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","BCDF","BK4588","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","IE00B64PRP62.GBP","BK4007","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649270626","title":"Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2649270626","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649270626?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:00","pubTimestamp":1783335600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, July  06, 2026  (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/06/3322307/0/en/Belite-Bio-Announces-Oral-Presentations-at-Two-Upcoming-Medical-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645025966","title":"Belite Bio CMO Hendrik Peter Scholl reports disposal of ADS worth $1.46 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2645025966","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645025966?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:06","pubTimestamp":1782122788,"startTime":"0","endTime":"0","summary":"shares by Chief Medical Officer Hendrik Peter Scholl on June 18, 2026.The transactions covered 10,000 American depositary shares sold at prices ranging from USD 143.90 to USD 147.11.Holdings reported indirectly through Bioptima Ltd. fell to 15,000 American depositary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL55TZG1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Belite Bio CMO Hendrik Peter Scholl reports disposal of ADS worth $1.46 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644717769","title":"Belite Bio CMO Hendrik Peter Scholl reports disposal of 10,000 common shares worth $1.41 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644717769","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644717769?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:04","pubTimestamp":1781690666,"startTime":"0","endTime":"0","summary":"Belite Bio Chief Medical Officer Hendrik Peter Scholl reported sales of 10,000 American depositary shares on June 16.Sales were executed indirectly through Bioptima Ltd. at prices ranging from USD 137.61 to USD 145.02 per share.Indirect beneficial ownership fell to 25,000 American depositary shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL7Pv9Sk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Belite Bio CMO Hendrik Peter Scholl reports disposal of 10,000 common shares worth $1.41 million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644715950","title":"Belite Bio (BLTE) Stock Could Be 35% Undervalued After Tinlarebant NDA Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2644715950","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644715950?lang=en_us&edition=fundamental","pubTime":"2026-06-17 13:30","pubTimestamp":1781674210,"startTime":"0","endTime":"0","summary":"Why Belite Bio Stock Is Back in Focus After Tinlarebant NDA Milestone\nBelite Bio (BLTE) is drawing attention after completing its rolling New Drug Application submission to the FDA for tinlarebant, an oral therapy candidate for Stargardt disease type 1, a rare inherited retinal condition with no approved treatments.\nSee our latest analysis for Belite Bio.\nBelite Bio’s latest regulatory milestone comes after a period where momentum has cooled in the share price, with the stock down 14.35% on a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/belite-bio-blte-stock-could-be-35-undervalued-after-tinlareb","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/belite-bio-blte-stock-could-be-35-undervalued-after-tinlareb","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643208740","title":"Belite Bio Price Target Maintained With a $200.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2643208740","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643208740?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:57","pubTimestamp":1781524620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLTE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 15, 2026 07:57 ET (11:57 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643270086","title":"Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Rhythm Pharmaceuticals (RYTM) and Belite Bio, Inc. ADR (BLTE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643270086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643270086?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:10","pubTimestamp":1781521813,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inventiva (IVA), Rhythm Pharmaceuticals (RYTM) and B...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-rhythm-pharmaceuticals-rytm-and-belite-bio-inc-adr-blte-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-rhythm-pharmaceuticals-rytm-and-belite-bio-inc-adr-blte-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU0128526141.USD","HCSG","XBI","BK4139","LU0029874061.USD","XLV","IVA","BK4588","BK4137","LABU","BLTE","BK4007","RYTM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643724746","title":"Belite Bio completes rolling submission of NDA to U.S. FDA for tinlarebant","url":"https://stock-news.laohu8.com/highlight/detail?id=2643724746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643724746?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:30","pubTimestamp":1781469005,"startTime":"0","endTime":"0","summary":"Belite Bio (BLTE) announced the completion of its rolling submission of a New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/belite-bio-completes-rolling-submission-of-nda-to-u-s-fda-for-tinlarebant-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/belite-bio-completes-rolling-submission-of-nda-to-u-s-fda-for-tinlarebant-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLTE","BK4007","LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643821607","title":"Belite Bio completes rolling FDA NDA submission for tinlarebant in Stargardt disease type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2643821607","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643821607?lang=en_us&edition=fundamental","pubTime":"2026-06-13 09:30","pubTimestamp":1781314215,"startTime":"0","endTime":"0","summary":"Belite Bio completed a rolling FDA New Drug Application for tinlarebant to treat Stargardt disease type 1.The submission began in April 2026 under Breakthrough Therapy Designation.The NDA now enters the FDA’s 60-day filing review; acceptance would trigger a PDUFA target action date.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260613:nNDL8l2VXQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BLTE","SG9999014021.USD","BK4007","LU2210149790.SGD","IE00BN0W2W23.USD","BK4112","LU2210150020.SGD","NDAQ","LU0314104364.USD","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD","IE00BKPKM429.USD","BK4588","IE00B64PRP62.GBP","BK4585","SG9999014039.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643219833","title":"Belite Bio - Application to Undergo 60-Day FDA Review; Pdufa Date to Be Assigned IF Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=2643219833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643219833?lang=en_us&edition=fundamental","pubTime":"2026-06-13 09:30","pubTimestamp":1781314200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260613:nTUABWLNDJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://investors.belitebio.com;belitebio.com","stockEarnings":[{"period":"1week","weight":0.0398},{"period":"1month","weight":0.0291},{"period":"3month","weight":0.016},{"period":"6month","weight":-0.1563},{"period":"1year","weight":1.3903},{"period":"ytd","weight":-0.0091}],"compareEarnings":[{"period":"1week","weight":0.0553},{"period":"1month","weight":0.0246},{"period":"3month","weight":0.0522},{"period":"6month","weight":0.1146},{"period":"1year","weight":0.2258},{"period":"ytd","weight":0.1289}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.020711},{"month":2,"riseRate":0.75,"avgChangeRate":0.070972},{"month":3,"riseRate":0.25,"avgChangeRate":-0.067883},{"month":4,"riseRate":0.25,"avgChangeRate":-0.011914},{"month":5,"riseRate":0.6,"avgChangeRate":0.032881},{"month":6,"riseRate":0.4,"avgChangeRate":0.163367},{"month":7,"riseRate":1,"avgChangeRate":0.188852},{"month":8,"riseRate":0.2,"avgChangeRate":0.077453},{"month":9,"riseRate":0.5,"avgChangeRate":0.027284},{"month":10,"riseRate":0.75,"avgChangeRate":0.224047},{"month":11,"riseRate":0.75,"avgChangeRate":0.12408},{"month":12,"riseRate":0.5,"avgChangeRate":0.042173}],"exchange":"NASDAQ","name":"Belite Bio, Inc.","nameEN":"Belite Bio, Inc.","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Belite Bio, Inc.(BLTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Belite Bio, Inc.,BLTE,Belite Bio, Inc.股票,Belite Bio, Inc.股票老虎,Belite Bio, Inc.股票老虎国际,Belite Bio, Inc.行情,Belite Bio, Inc.股票行情,Belite Bio, Inc.股价,Belite Bio, Inc.股市,Belite Bio, Inc.股票价格,Belite Bio, Inc.股票交易,Belite Bio, Inc.股票购买,Belite Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Belite Bio, Inc.(BLTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction